📌 Key Takeaways
- Topic: Is Silicon Dioxide Acidic or Basic? Its Acidic Oxide Behavior Explained
- Keywords: silica melting point
- Published: 2026-11-20 01:32:07
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
How Is Silica Made? Production Methods for Each Type of Silica
- Quartz Powder Supplier: Grades, Purity and How to Evaluate Suppliers
- How to Choose a Silica Supplier: Key Criteria, Certifications and Red Flags
- What Is Diatomaceous Earth? Composition, Grades and Common Uses
- Silica for Paint: Matting, Anti-Settling and Rheology Functions Explained
- MSNs are gradually being developed as promising drug delivery carriers due to their brilliant biocompatibility, biodegradability, and greatly ordered pore structure. Owing to the great flexibility in tuning the surface properties of MSNs, specific surface functionalization modification of MSNs can achieve precise modulation of drug delivery behavior, thus to meet the application requirements. Currently, the most researched is the construction of stimuli-responsive MSNs-based drug delivery system (Fig. 6c ), i.e., when MSNs reach the lesion site, the release of drugs is controllably stimulated by specific internal or external components, thus achieving the improved drug utilization and staying away from drug leakage at non-lesion sites. 259, 272, 331 The most core step in this process is connecting some caps with stimulus-responsive properties onto the MSNs surface, which can be called gatekeepers, 119, 158 nanovalves, 332, 333 or others. Once the therapeutic drug is filled into the mesopore of MSNs, the pore entrances are blocked by the caps to prevent the drug from diffusing out. Under normal physiological conditions, the caps always keep the pores in a closed state, but when reaching to the lesion, the caps are separated under the stimulation of certain components, which in turn induces targeted on-demand release of drugs. These caps can be polymers, 334 metal/metal compound NPs, 170, 335 biomolecules, 336 etc. While exogenous stimuli such as light, ultrasound, magnetic field and electric field, endogenous stimuli such as temperature, pH, redox agents, and enzymes, can activate the caps. Several examples about the surface modification of MSNs and the corresponding stimuli-responsive plans are briefly clarified here.
Silica as an Anti-Settling Agent: How It Keeps Pigments and Fillers Suspended
What is silica (SiO₂)?
silica supplier Thailand
What is the difference between fumed silica and precipitated silica?
silica 99.99% Fang, W., Yang, J., Gong, J. & Zheng, N. Photo‐and pH‐triggered release of anticancer drugs from mesoporous silica‐coated Pd@Ag nanoparticles. Adv. Funct. Mater. 22, 842-848 (2012). Post CAS Google Scholar
What drives silica raw material prices?
silica supplier Japan Clinical trials involving mesoporous silica have been ongoing since 2007, discussing its potential in diverse biomedical applications (Table 3 ). To date, the clinical trials have revealed the safety and good tolerability of silica in human subjects. In 2014, MSNs as oral delivery carriers for boosting the pharmacokinetic profile of drugs with limited aqueous solubility were reported. 500 A silica NPs-lipid hybrid formulation loading with ibuprofen (Lipoceramic-IBU) was prepared. The randomized, double-blind, single-dose oral administration study (20 mg ibuprofen) was conducted on 16 healthy male volunteers. The bioavailability of Lipoceramic-IBU was found to be 1.95 times higher than that of the commercial tablet Nurofen. 500 This result suggested the secure and effective use of silica-based NPs in mimicking food impacts to optimize the oral absorption of drugs with poor water solubility. In another clinical trial consisting of 12 participants in 2016, the bioavailability of ordered MSNs-based fenofibrate formulation raised by 54.1% after a single oral dose, when compared to the commercial formulation Lipanthyl. 39 Owing to the potentially perfect clinical outcomes of silica-based nanocarriers, the pharmacokinetics, safety, and metabolic profile of a hybrid core-shell silica NP (named Cornell dots, C dots) with a diameter of 6 nm functionalized with 124 I, targeting peptide cyclo-(Arg-Gly-Asp-Tyr), and Cy5 ( 124 I-cRGDY-PEG-C' dots) is first conducted in humans utilizing PET imaging and clinical tracer at clinical trials in 2014 (NCT01266096). 58 Results showed the good safety and reproducible PK signatures of C dots with the whole-body clearance half-time of 13-21 h after intravenous administration in patients, which is shorter than 111 In labeled liposomes and 131 I-labeled humanized monoclonal antibody A33. These findings verified the possibility of these NPs for cancer diagnostics in humans. 58 Similarly, 8 nm core-shell silica NPs encapsulated with Cy5.5 in the core and connected with cRGDY on the surface (cRGDY-PEG-Cy5.5-nanoparticles) were used in patients at nanomole doses for sentinel lymph nodes detection of head and neck melanoma at a phase 1/2 human clinical trial. 501 The incredible safety, accuracy, reliability, and high contrast of these particles for visual identification of sentinel lymph nodes are irreplaceable by other available imaging molecules presently, of which phase 2 clinical trial is ongoing and will be finished in 2024 (NCT02106598). Meanwhile, another two clinical trials based on C dots are carried out. In 2018, the 89 Zr-DFO-cRGDY-PEG-Cy5-C' dots tracers were first used in both surgical and non-surgical patients for PET-CT imaging of malignant brain tumors in phase 1 clinical trial (NCT03465618). The distribution and removal profiles from the body of these particles will also be assessed till 2023. In 2019, 64 Cu-NOTA-PSMA-PEG-Cy5.5-C' dots tracer was used in another human phase 1 clinical trial for guiding the surgery of prostate cancer by PET and MRI imaging (NCT04167969).As a nanocomposite with high safety and brilliant photothermal conversion efficiency, the silica-gold NPs have also been shown to be potential therapeutic agents for plasmonic photothermal therapy of atherosclerosis (NCT01270139), 502, 503 and photothermal ablation of tumors (NCT00848042, NCT04240639). 40 In addition, an engineered mesoporous silica (SiPore15) with particle size of 1.1-1.5 μm × 0.2-0.4 μm was developed by Baek et al., and they revealed that such pure synthetic amorphous silica could remarkably decrease long-term blood glucose levels, showing good promise for the treatment of prediabetes (NCT03823027). 504 In other clinical trials, an amorphous silica-containing bioactive scaffold, called Siloss, was used to promote bone regeneration, and could be replaced by natural bone due to its fully resorbable nature (NCT02639572), and the silica-calcium phosphate nanocomposite (SCPC) was developed as graft material for the reconstruction of the volume-deficient alveolar ridges (NCT05317039). In all, these clinical trials reveal the safety and efficacy of MSNs in diverse biomedical application scenarios.
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.